Assessment of ablative margin after radiofrequency ablation for hepatocellular carcinoma; Comparison between magnetic resonance imaging with ferucarbotran and enhanced CT with iodized oil deposition

European Journal of Radiology

Volumn 81, Issue 7, 2012, Pages 1400-1404

  Koda, Masahiko ^a   Tokunaga, Shiho ^a   Fujise, Yuki ^a   Kato, Jun ^a   Matono, Tomomitsu ^a   Sugihara, Takaaki ^a   Nagahara, Takakazu ^a   Ueki, Masaru ^a   Murawaki, Yoshikazu ^a   Kakite, Suguru ^a   Yamashita, Eijiro ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Ablative margin; Enhanced CT; Ferucarbotran; Hepatocellular carcinoma; Iodized oil; Radiofrequency ablation

Indexed keywords

FERUCARBOTRAN; IODINATED POPPYSEED OIL;

ABLATIVE MARGIN; ARTICLE; CANCER GRADING; CHEMOEMBOLIZATION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; GOLD STANDARD; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; LIVER CELL CARCINOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RADIOLOGICAL PARAMETERS; TUMOR VOLUME;

AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; CONTRAST MEDIA; DEXTRANS; EPIRUBICIN; FEMALE; HUMANS; IODIZED OIL; IOPAMIDOL; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MAGNETITE NANOPARTICLES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TOMOGRAPHY, SPIRAL COMPUTED; TREATMENT OUTCOME;

EID: 84861637516     PISSN: 0720048X     EISSN: 18727727     Source Type: Journal    
DOI: 10.1016/j.ejrad.2011.03.004     Document Type: Article

References (26)

1. R.E. Schwarz, and D.D. Smith Trends in local therapy for hepatocellular carcinoma and survival outcomes in the US population Am J Surg 195 6 2008 829 836
2. S. Garrean, J. Hering, A. Saied, W.S. Helton, and N.J. Espat Radiofrequency ablation of primary and metastatic liver tumors: a critical review of the literature Am J Surg 195 4 2008 508 520
3. K.K. Ng, R.T. Poon, C.-M. Lo, J. Yuen, W.K. Tso, and S.-T. Fan Analysis of recurrence pattern and its influence on survival outcome after radiofrequency ablation of hepatocellular carcinoma J Gastrointest Surg 12 1 2008 183 191
4. J.A. Vossen, M. Buijs, and I.R. Kamel Assessment of tumor response on MR imaging after locoregional therapy Tech Vasc Interventional Radiol 9 3 2006 125 132
5. M.-H. Park, H. Rhim, Y.-S. Kim, D. Choi, H.K. Lim, and W.F. Lee Spectrum of CT findings after radiofrequency ablation of hepatic tumors RadioGraphics 28 2 2008 379 392
6. T. Okusaka, S. Okada, and H. Ueno Satellite lesions in patients with small hepatocellular carcinoma with reference to clinicopathological features Cancer 95 9 2002 1931 1937
7. K. Ikeda, T. Seki, and H. Umehara Clinicopathological study of small hepatocellular carcinoma with microscopic satellite nodules to determine the extent of tumor ablation by local therapy Int J Oncol 31 3 2007 485 491
8. S. Mulier, Y. Ni, J. Jamart, T. Ruers, G. Marchal, and L. Michel Local recurrence after hepatic radiofrequency coagulation. Multivariate meta-analysis and review of contributing factors Ann Surg 242 2 2005 158 171
9. A.A. Zytoon, H. Ishii, and K. Murakami Recurrence-free survival after radiofrequency ablation of hepatocellular carcinoma. A registry report of the impact of risk factors on outcome Jpn J Clin Oncol 37 9 2007 658 672
10. Z.-W. Peng, Y.-J. Zhang, and M.-S. Chen Risk factors of survival after percutaneous radiofrequency ablation of hepatocellular carcinoma Surg Oncol 17 1 2008 23 31
11. N. Nishijima, Y. Ohsaki, and R. Kita Proposal of the radicality grading as a criterion for therapeutic effectiveness of RFA against hepatocellular carcinoma, in relation to the local recurrence rate Kanzo 49 5 2008 192 199
12. K. Mori, K. Fukuda, and H. Asaoka Radiofrequency ablation of the liver: determination of ablative margin at MR imaging with impaired clearance of ferucarbotran-feasibility study Radiology 251 2 2009 557 565
13. D.D. Stark, R. Weissleder, and G. Elizondo Superparamagnetic iron oxide: clinical application as a contrast agent for MR imaging of the liver Radiology 168 2 1988 297 301
14. Y. Imai, T. Murakami, and S. Yoshida Superparamagnetic iron oxide-enhanced magnetic resonance images of hepatocellular carcinoma: Correlation with histological grading Hepatology 32 2 2000 205 212
15. K. Liu, X. He, and X.-Z. Lei Pathomorphological study on location and distribution of Kupffer cells in hepatocellular carcinoma World J Gastroenterol 9 9 2003 1946 1949
16. M. De Santis, S. Alborino, P.L. Tartoni, P. Torricelli, A. Casolo, and R. Romagnoli Effects of lipiodol retention on MRI signal intensity from hepatocellular carcinoma and surrounding liver treated by chemoembolization Eur Radiol 7 7 1997 10 16
17. M. Tsuda, K. Majima, T. Yamada, H. Saitou, T. Ishibashi, and S. Takahashi Hepatocellular carcinoma after radiofrequency ablation therapy dynamic CT evaluation of treatment Clin Imaging 25 6 2001 409 415
18. S. Smith, and A. Gillams Imaging appearances following thermal ablation Clin Radiol 63 1 2008 1 11
19. Tokunaga S, Koda M, Matono T, et al. Assessment of ablative margin by magnetic resonance imaging with ferucarbotran in radiofrequency ablation for liver cancer; Comparison with enhanced CT. Brit J Radiol 2011; doi:10.1259/bjr/64518148.
20. A. Tanimoto, K. Oshio, M. Suematsu, D. Pouliquen, and D.D. Stark Relaxation effects of clustered particles J Magn Reson Imaging 14 1 2001 72 77
21. S.H. Kim, D. Choi, and S.H. Kim Ferucarbotran-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma Am J Roentgenol 184 4 2005 1069 1076
22. Y.K. Kim, H.S. Kwak, C.S. Kim, G.H. Chung, Y.M. Han, and J.M. Lee Hepatocellular carcinoma in patients with chronic liver disease: comparison of SPIO-enhanced MR imaging and 16-detector row CT Radiology 238 2 2006 531 541
23. M. Iwasa, H. Tanaka, N. Fujita, Y. Kobayashi, and Y. Takei Difficulty differentiating ablative margin from necrotic tumor at MR imaging with impaired ferucarbotran clearance Radiology 252 3 2009 931
24. P. Reimer, and T. Balzer Ferucarbotran (Resovist): a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development, and applications Eur Radiol 13 6 2003 1266 1276
25. M.F. Bellin, J.A. Webb, A.J. Van Der Molen, H.S. Thomsen, and S.K. Morcos Members of Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR) Safety of MR liver specific contrast media Eur Radiol 15 8 2005 1607 1614
26. H. Onishi, T. Murakami, and T. Kim Safety of ferucarbotran in MR imaging of the liver: a pre- and postexamination questionnaire-based multicenter investigation J Magn Reson Imaging 29 1 2009 106 111